Novo Nordisk Shares Plunge After Heart Drug Ziltivekimab Fails Late-Stage Trial
On July 31, 2026, Novo Nordisk announced its experimental heart drug ziltivekimab failed to reduce major adverse cardiovascular events in a Phase 3 trial involving over 6,300 high-risk patients. The stock fell up to 10%, wiping out over $30 billion in market value. The failure removes a key non-obesity growth opportunity, as the company faces intense competition from Eli Lilly and a 70% share decline from its mid-2024 peak.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection
Cross-source coverage
Wire timeline
Novo Nordisk shares plunge after heart drug Ziltivekimab fails late-stage trial
Novo Nordisk's stock fell sharply on July 31, 2026, after its experimental heart drug Ziltivekimab failed the main goal of the Phase 3 ZEUS trial. The drug, a once-monthly injection targeting inflammation via IL-6 blockade, showed a hazard ratio of 0.99, meaning no reduction in major cardiovascular events compared to placebo. The trial involved over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. While the drug lowered inflammation markers, this did not translate into clinical benefit. Patients on Ziltivekimab had more serious infections. The failure is a major setback for Novo Nordisk's efforts to diversify beyond its blockbuster weight-loss and diabetes drugs Wegovy and Ozempic. The company expects a non-cash impairment charge in Q3 2026 but maintained its full-year adjusted operating profit outlook. Novo shares have already been under pressure in 2026 due to competition from Eli Lilly's Mounjaro and Zepbound.
Novo Nordisk shares plunge after heart drug Ziltivekimab fails late-stage trial
Novo Nordisk's stock fell sharply on July 31, 2026, after its experimental heart drug Ziltivekimab failed the main goal of the large late-stage ZEUS trial. The drug, a once-monthly injection targeting inflammation via IL-6 blockade, did not reduce major adverse cardiovascular events in over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. The hazard ratio was 0.99, indicating no benefit over placebo. Patients on the drug had more serious infections. The failure is a major setback for Novo Nordisk's efforts to diversify beyond its blockbuster weight-loss and diabetes drugs Wegovy and Ozempic. The company expects a non-cash impairment charge in Q3 2026 but maintained its full-year operating profit outlook. The stock drop reflects investor disappointment as analysts had projected billions in potential sales for Ziltivekimab.
Novo Nordisk Shares Plunge After Key Heart Drug Trial Fails
Novo Nordisk shares fell 9.4% after its experimental heart drug ziltivekimab failed a critical Phase 3 clinical trial called Zeus. The drug, a monthly injection targeting IL-6 to reduce inflammation, successfully lowered inflammatory markers but did not reduce the risk of major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. Additionally, patients receiving the drug experienced more serious infections. The failure is a setback for Novo Nordisk's efforts to expand beyond diabetes and weight-loss drugs. Two other trials (Hermes and Artemis) are still ongoing but now face lower expectations. The company maintained its 2026 adjusted operating profit outlook, though it will take a non-cash impairment charge. The article questions whether the dip is a buying opportunity, noting the drop was smaller than two 17% declines in February 2026.
Show 4 older updatesHide older updates
Novo Nordisk Stock Plunges 9% After Heart Drug Ziltivekimab Fails Pivotal Trial
Novo Nordisk's U.S.-listed shares closed 8.8% lower on July 31, 2026, after its experimental cardiovascular drug ziltivekimab failed a Phase 3 trial. The ZEUS trial enrolled over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammation. While the drug successfully inhibited the IL-6 inflammatory pathway and reduced biomarkers, it did not reduce cardiovascular deaths, non-fatal heart attacks, or non-fatal strokes, yielding a hazard ratio of 0.99 (virtually no difference from placebo). Serious infections occurred more frequently in the treatment group. The failure removes one of Novo Nordisk's most promising opportunities to diversify beyond its obesity and diabetes drugs (Wegovy, Ozempic), which generate over 90% of sales. Consensus estimates had projected peak annual sales of $3 billion for ziltivekimab. Novo Nordisk will record a non-cash impairment charge but maintained its 2026 adjusted operating-profit outlook. Two additional ziltivekimab trials will continue, though analysts are increasingly skeptical.
Novo Nordisk Stock Plummets as Heart Drug Ziltivekimab Fails Late-Stage Trial
Novo Nordisk (NVO) shares fell sharply on July 31, 2026, after the company announced that its experimental anti-inflammatory drug, ziltivekimab, failed to meet its primary endpoint in a late-stage cardiovascular trial. The Phase 3 ZEUS trial evaluated monthly 15 mg doses in over 6,300 high-risk patients with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation. Although the drug successfully inhibited the IL-6 inflammatory pathway, it did not reduce major adverse cardiovascular events compared to placebo. Investors reacted negatively as ziltivekimab was seen as key to diversifying Novo Nordisk's revenue beyond its GLP-1 franchise. The stock is now down over 10% year-to-date. Despite the setback, analysts note the stock remains above its 100-day and 200-day moving averages, trades at a forward P/E of about 15x, and offers a 3.84% dividend yield. Wall Street consensus is currently 'Hold' with a mean price target of ~$47. The company is scheduled to report Q2 earnings on August 5, with consensus EPS of $0.81.
Novo Nordisk Loses $30 Billion in Market Value After Heart Drug Trial Failure
Novo Nordisk shares plunged 9.3% on Friday, wiping out over $30 billion in market capitalization after the Danish drugmaker announced its experimental drug ziltivekimab failed to reduce major adverse cardiovascular events in a late-stage clinical trial. The failure drew sharp criticism from analysts, who said the drug would have needed to show at least a 20% risk reduction to be viable. Jeffries analysts called the results 'strategically negative,' noting they erased a potential $10 billion annual growth opportunity beyond Novo Nordisk's Ozempic and Wegovy franchises. Goldman Sachs had previously praised the drug's potential to build a cardiovascular disease franchise. The company's market cap fell from $229.2 billion to $198.5 billion, representing a nearly 69% decline from its June 2024 all-time high of $635.7 billion. The setback comes as Novo Nordisk continues efforts to expand into pill versions of its GLP-1 medications and faces a legal dispute with rival Eli Lilly over advertising claims.
Novo Nordisk Shares Plunge After Heart Drug Ziltivekimab Fails Late-Stage Trial
Novo Nordisk shares fell as much as 10% on July 31, 2026, after the Danish drugmaker announced that its experimental heart drug, ziltivekimab, failed to achieve a statistically significant reduction in major adverse cardiovascular events (MACE) compared to a placebo in a late-stage trial involving over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammation. While the drug showed some biological effect, it did not translate into meaningful clinical benefit. Chief Scientific Officer Martin Holst Lange reaffirmed the company's strategic commitment to cardiovascular disease despite the setback. The failed trial is the latest blow to Novo Nordisk's pipeline, coming after disappointing results for its next-generation weight-loss drug CagriSema earlier in 2026. Analysts at Jefferies and Citi called the share move disproportionate given ziltivekimab's small portfolio contribution, but noted the result is strategically negative as it removes a key non-obesity growth opportunity. The company's shares have fallen about 70% from their mid-2024 peak amid intense competition from Eli Lilly.